Im Cannabis Corp (IMCC)vsNovartis AG ADR (NVS)
IMCC
Im Cannabis Corp
$0.12
+0.26%
HEALTHCARE · Cap: $1.09M
NVS
Novartis AG ADR
$156.15
-1.45%
HEALTHCARE · Cap: $290.96B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 111259% more annual revenue ($56.69B vs $50.91M). NVS leads profitability with a 22.5% profit margin vs -27.3%. NVS earns a higher WallStSmart Score of 51/100 (C-).
IMCC
Avoid31
out of 100
Grade: F
NVS
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+20.3%
Fair Value
$1.48
Current Price
$0.12
$1.36 discount
Margin of Safety
-70.9%
Fair Value
$92.73
Current Price
$156.15
$63.42 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 31.8%
Keeps 23 of every $100 in revenue as profit
Generating 5.6B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -119.8% — below average capital efficiency
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : IMCC
The strongest argument for IMCC centers on Debt/Equity.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 31.8%.
Bear Case : IMCC
The primary concerns for IMCC are EPS Growth, Market Cap, Piotroski F-Score.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Key Dynamics to Monitor
IMCC profiles as a turnaround stock while NVS is a value play — different risk/reward profiles.
IMCC carries more volatility with a beta of 2.04 — expect wider price swings.
NVS is growing revenue faster at 0.8% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 31/100), backed by strong 22.5% margins. IMCC offers better value entry with a 20.3% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Im Cannabis Corp
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
IM Cannabis Corp. The company is headquartered in Tel Aviv-Yafo, Israel.
Visit Website →Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?